结直肠癌腹膜转移患者术中行雷替曲塞腹腔灌注化疗的安全性研究  

Study on the Safety of Intraoperative Rhatitrexide Intraperitoneal Perfusion Chemotherapy in Patients with Peritoneal Metastasis of Colorectal Cancer

作　　者：王贺 孙合辰 马丽敏 张兆伟[1] 张洪军[1] WANG He;SUN Hechen;MA Limin;ZHANG Zhaowei;ZHANG Hongjun(Department of Gastrointestinal Surgery,Shan County Central Hospital,Heze 274300,Shandong,China)

机构地区：[1]单县中心医院胃肠外科,山东菏泽274300

出　　处：《中外医疗》2024年第21期13-16,共4页China & Foreign Medical Treatment

摘　　要：目的分析结直肠癌腹膜转移患者术中雷替曲塞腹腔灌注化疗的安全性。方法随机选取2021年3月—2023年10月单县中心医院收治的120例结直肠癌腹膜转移患者为研究对象,依据治疗方法的不同分为参照组(n=60)和观察组(n=60),参照组行腹腔镜下结直肠癌根治术,观察组在参照组的基础上,于术中行雷替曲塞腹腔灌注化疗治疗,比较两组患者手术前后免疫功能、术后并发症及不良反应发生率。结果术前,两组患者免疫功能比较,差异无统计学意义(P>0.05);术后3 d两组患者免疫功能均有改善,且观察组CD4^(+)(55.61±2.20)%高于参照组(50.89±2.14)%,观察组CD8^(+)为(36.09±1.52)%低于参照组的(39.04±1.61)%、观察组CD4^(+)/CD8^(+)(1.28±0.20)高于参照组(1.15±0.23),差异有统计学意义(t=11.912、10.320、3.304,P均<0.05)。两组患者术后并发症、不良反应发生率比较,差异无统计学意义(P均>0.05)。结论在结直肠癌腹膜转移患者手术治疗中实施雷替曲塞腹腔灌注化疗治疗可以降低手术对免疫功能的影响,具有良好的治疗安全性,不会明显增加不良反应。Objective To analyze the safety of intraoperative rhatitrexide intraperitoneal chemotherapy in patients with peritoneal metastasis of colorectal cancer.Methods A total of 120 patients with peritoneal metastasis of colorectal cancer admitted to the Central Hospital of Shan County from March 2021 to October 2023 were randomly selected as the study objects,and were divided into the reference group(n=60)and the observation group(n=60)according to the different treatment methods.Reference group underwent laparoscopic radical resection of colorectal cancer,and the observation group received intra-abdominal perfusion chemotherapy with rhatitrexed during the operation on the basis of the reference group.The incidence of immune function,postoperative complications and adverse reactions before and after operation were compared between the two groups.Results Before operation,there was no significant difference in immune function between the two groups(P>0.05).The immune function of both groups was improved 3 days after operation,and CD4^(+)in observation group was(55.61±2.20)%,which was higher than(50.89±2.14)%in reference group.CD8^(+)in the observation group was(36.09±1.52)%,which was lower than(39.04±1.61)%in the reference group,CD4^(+)/CD8^(+)in the observation group was(1.28±0.20),which was higher than(1.15±0.23)in the reference group,and the differences were statistically significant(t=11.912,10.320,3.304,all P<0.05).There was no significant difference in the incidence of postoperative complications and adverse reactions between two groups(both P>0.05).Conclusion In the surgical treatment of patients with peritoneal metastasis of colorectal cancer,intra-abdominal perfusion chemotherapy with raltitrexel can reduce the effect of surgery on immune function,has a good therapeutic safety,and does not significantly increase the occurrence of adverse reactions.

关 键 词：结直肠癌 腹膜转移 雷替曲塞 腹腔灌注化疗 免疫功能 安全性 不良反应 

分 类 号：R735[医药卫生—肿瘤]